Introduction
Once, the utility of recombinant DNA technology in generating drugs was limited to producing wild-type human proteins in heterologous hosts. Now, protein engineering is being used to tailor proteins for specific clinical applications. The resulting biologic drugs can provide a level of target specificity not achievable with small molecules (Szlachcic et al., 2011) .
The mammalian pancreatic-type ribonucleases (ptRNases) are especially well suited for exploitation as chemotherapeutic agents. These enzymes circumvent the pitfalls that plague many other protein-based drugs, such as high molecular mass, instability, and immunogenicity. ptRNases comprise a highly conserved family of small ($13 kDa), secreted proteins that catalyze the degradation of RNA with extremely high efficiency (D'Alessio and Riordan, 1997; Raines, 1998) . Incredibly, mammalian cells internalize these enzymes readily (Fig. 11 .1); thus, ptRNases are not restricted to the extracellular or cell-surface targets of most other protein-based agents (Carter, 2011) . Moreover, whereas many promising proteins never achieve success in the clinic because they are hampered by problems with production, storage, and administration (Szlachcic et al., 2011) , ptRNases are produced readily in microbial hosts, have unusually high conformational stability, and maintain their integrity in extracellular fluids and tissues.
Recently, ptRNases have garnered much attention because several of them, including the dimeric bovine seminal ribonuclease (BS-RNase) and an amphibian ortholog, Onconase (ONC), have proven to be natural cytotoxins for human cancer cells. ONC is currently in a Phase IIIb confirmatory clinical trial as a second-line chemotherapeutic agent for malignant mesothelioma and has been granted both orphan-drug and fast-track status by the US Food and Drug Administration (Lee and Raines, 2008; Mikulski Figure 11.1 The internalization pathway of ptRNases involves association with glycans on the cell membrane, absorptive endocytosis, and interaction with cytosolic RI. Upon evasion of RI, cytotoxic ptRNases can degrade cellular RNA and induce apoptosis. et al., 2002) . Despite their inherent cytotoxicity, both BS-RNase and ONC are of limited clinical utility. For example, ONC is compromised by doselimiting renal toxicity and high immunogenicity relative to mammalian ribonucleases (Matoušek et al., 2003; Pavlakis and Vogelzang, 2006) . Moreover, cytotoxic variants of mammalian ptRNases have greater specificity than ONC for cancer cells (Rutkoski et al., 2005) . Efforts to exploit naturally occurring microbial and fungal ribotoxins have been plagued by similar immunogenicity and low specificity (for reviews, see Ardelt et al., 2009; Fang and Ng, 2011) . Hence, the future of ptRNases as chemotherapeutic agents appears to rely on the strategic development of the mammalian homologues .
Although mammalian ptRNases possess the necessary stability, catalytic activity, and nonimmunogenicity to warrant consideration as potential chemotherapeutic agents, their success is limited by two substantial barriers: internalization into the cytosol of target cells and inhibition by the cytosolic ribonuclease inhibitor (RI) protein, which binds with femtomolar affinity to most ptRNases but not BS-RNase or ONC ( Fig. 11 .2) (Dickson et al., 2005) . To design ptRNase-based agents, we have sought to understand the underlying biophysical and biochemical basis for their mechanism of action and then to translate that knowledge into optimized proteins.
A useful ptRNase-based cytotoxin must catalyze the degradation of RNA within target cells. To do so, it must gain entry to the cytosol, Figure 11 .2 Three-dimensional structure of the human RIÁRNase 1 complex (Protein Data Bank entry 1z7x). The active-site histidine residues 12 and 119 of RNase 1 are depicted explicitly, and the N-and C-termini of RI are labeled. The complex has Johnson et al., 2007b) .
evade RI there, and retain its catalytic activity throughout the process. Here, we report on our current understanding of these requirements and our strategies for engineering ptRNases that achieve maximal therapeutic efficacy. We also provide details on the assays that we use to evaluate relevant attributes of putative ptRNase cytotoxins. Although we focus on the well-known enzymes from cow (RNase A) and human (RNase 1), the methodologies are applicable to other ptRNases as well.
Attributes of Cytotoxic ptRNases
2.1. Catalytic activity and proteolytic stability ; ) that is among the highest known for an enzyme-catalyzed reaction. This activity leads to cellular apoptosis (Bretscher et al., 2000) and is essential for ptRNase-mediated cytotoxicity (Kim et al., 1995) . Proteins with high thermostability tend to have low susceptibility to proteolytic degradation (Parsell and Sauer, 1989) . This premise holds true for ptRNases, as installing an additional disulfide bond in RNase A significantly increases its thermostability, resistance to proteolysis, and cytotoxicity . Accordingly, when choosing residues to alter within ptRNases, care must be taken to avoid interference with active-site residues, cysteine residues that participate in disulfide bonds, and other residues critical to structure and function (Fig. 11.3; Smith and Raines, 2006) . Although no consensus exists regarding the minimal requirements for either parameter, decreasing catalytic activity or thermostability leads to decreases in cytotoxicity Leland et al., 2000) . Catalytic activity can be measured by using a fluorogenic substrate, such as 6-carboxyfluoresceindArUdAdA-6-carboxytetramethylrhodamine (Kelemen et al., 1999; ; thermostability can be monitored by ultraviolet or circular dichroism spectroscopy.
Cellular internalization
ptRNases are especially well suited as biologic drugs due to their endogenous ability to enter cells without requiring any additional delivery strategy. Still, ptRNase internalization remains an inefficient process and could limit cytotoxicity. To design a ptRNase-based drug that is equipped for more efficient internalization, it is important to understand the pathway by which ptRNases enter cells (Fig. 11.1 ).
Mammalian ptRNases undergo endocytosis through an adsorptive process that is nonsaturable, non-receptor mediated, and dynamin independent . Certain anionic cell-surface molecules facilitate Coulombic interactions with cationic ptRNases, which are highly positively charged (Table 11 .1). Analyses in vitro and in cellulo reveal that RNase A interacts tightly with abundant anionic cell-surface glycosaminoglycans such as heparan sulfate and chondroitin sulfate, as well as sialic acid-containing glycoproteins. The uptake of RNase A correlates with cell-surface anionicity and could endow mammalian ptRNases with selective cytotoxicity for cancerous cells (Chao et al., 2010) . Following endocytosis, a very small fraction of the endosomal ptRNase is able to translocate into the cytosol and catalyze RNA degradation.
Specific modifications to a ptRNase can exploit the Coulombic interactions that likely facilitate RNase internalization (for a review, see Rutkoski and Raines, 2008) . Recent work has demonstrated that the amount of positive charge, as well as the distribution of that charge, can affect ptRNase adsorption (Turcotte et al., 2009) . For example, replacing two anionic surface residues, Glu49 and Asp53 (Fig. 11. 3), with arginines (arginine grafting) results in enhanced internalization and cytotoxicity of an RNase A variant (Fuchs et al., 2007) . Similarly, chemical cationization of ptRNases by amidation of carboxyl groups with either ethylenediamine or polyethylenimine leads to enhanced internalization and cytotoxicity (Futami and Yamada, 2008) . ptRNases can also be fused to cationic cell-penetrating peptides such as nonaarginine to increase internalization (Fuchs and Raines, 2005; Fuchs et al., 2007) . These cationic moieties need not be appended to ptRNases, as the addition of a cationic poly(aminoamine) dendrimer in trans increases the internalization and cytotoxicity of a ptRNase (Ellis et al., 2011) . We note, however, that increasing the positive charge of a ptRNase can have the adverse effect of increasing its affinity for RI, which is highly anionic ( Johnson et al., 2007a) .
Evading the ribonuclease inhibitor protein
RI is an $50-kDa protein found exclusively in the cytosol of mammalian cells. Multiple biological roles for RI have been proposed, including protecting cells from internalized secretory ptRNases and maintaining cellular redox homeostasis (Dickson et al., 2005; Monti et al., 2007) . Despite the uncertainty surrounding its precise physiological role(s), RI binds to members of the mammalian ptRNase superfamily with a 1:1 stoichiometry, completely inhibiting their catalytic activity by steric occlusion of the enzymic active site ( Fig. 11. 2). Because ribonucleolytic activity is necessary to induce cellular apoptosis, a cytotoxic ptRNase must evade RI. Nevertheless, as the noncovalent complexes formed between RI and its ligands are among the tightest known in biology, instilling RI evasion is a difficult task.
The goal of RI-evasion strategies is to modify the ptRNase so as to perturb only its interaction with RI. Many strategies are possible (for a review, see Rutkoski and Raines, 2008) . Recent analyses of various crystallized RIÁptRNase complexes indicate that, although the interaction of RI with various ptRNases is similar, evasion strategies should be optimized to recognize the subtle differences that exist in the binding interfaces. Computational analyses can be used to identify which residues of a ptRNase make the most contacts with RI (Rutkoski et al., 2005) . These residues can then be targeted for substitution through site-directed mutagenesis. We have found that introducing electrostatic and steric incompatibilities in these regions destabilize the RIÁRNase complex and that disruption is often best achieved by replacing small neutral or anionic residues in a ptRNase with arginine ( Fig. 11.3) . Arginine, as the most polar and second largest amino acid, can generate electrostatic repulsion and steric strain while increasing positive molecular charge, thereby enhancing internalization.
Our initial engineering efforts yielded a prototype ptRNase cytotoxin, G88R RNase A. The modification of a single residue imbued native RNase A with 10,000-fold lower affinity for RI and cytotoxicity (Leland et al., 1998) . Guided by computational algorithms, we have designed second-generation variants of RNase A and RNase 1 that evade RI more efficiently. For example, D38R/R39D/N67R/G88R RNase A demonstrates 20 million-fold lower affinity for RI than does native RNase A with little change to catalytic activity or thermostability (Table 11 .1). This variant is more toxic than ONC to human cancer cells (Rutkoski et al., 2005) . In addition to altering the RI-binding interface of RNase A, we find that appending a folate moiety at residue 88 engenders RI-evasion through steric repulsion (Smith et al., 2011) . The pendant folate also enhances targeting to and uptake by cells that overexpress the cell-surface folate receptor, as do many types of cancer cells. Benefit is also accrued by attaching a pendant poly(ethylene glycol) (PEG) moiety to RNase A at the same position. Beyond RI-evasion, PEG conjugation elicits markedly decreased renal clearance and increased tumor-growth inhibition in mice (Rutkoski et al., 2011) .
Human RNase 1 proved to be a greater challenge, as it binds to RI with 10 2 -fold higher affinity than does RNase A. Although R39D/N67D/ N88A/G89D/R91D RNase 1 has six billion-fold lower affinity for RI ( Johnson et al., 2007b) than does wild-type RNase 1, this variant is not as cytotoxic as D38R/R39D/N67R/G88R RNase A. An alternative strategy to engender RI-evasion is to bypass RI contact altogether. The human ptRNase variant PE5 carries a noncontiguous nuclear localization signal and has been shown to possess potent cytotoxicity that is dependent upon its nuclear uptake (Tubert et al., 2011) .
BS-RNase is a naturally dimeric homologue of RNase A that evades RI. But upon entry into the cytosol, the dimer dissociates and the resulting monomers are inhibited by RI (Lee and Raines, 2005) . Recently, the endogenous properties of BS-RNase have been recapitulated by creating genetically encoded or chemically conjugated multimers of ptRNases that are unable to dissociate in cellulo (Leich et al., 2006 (Leich et al., ,2007 Rutkoski et al., 2010) . Still, aspects of the mechanism of action of these multimers remain unclear. Multimeric ptRNases can be more cytotoxic than BS-RNase despite being less RI-evasive. Hence, the enhanced cytotoxicity demonstrated could be due, in part, to improved interaction of the multimers with the negatively charged cell membrane, thereby favoring endocytosis (Arnold et al., 2011; Leich et al., 2006; Rutkoski et al., 2010) . High cytosolic localization of tandem RNase A dimers supports this hypothesis (Leich et al., 2007) .
Assays to Evaluate the Cytotoxicity of ptRNases
Just as effort has gone into the rational design of cytotoxic ptRNases, so too has substantial work been done to develop assays to measure and characterize the cytotoxicity of ptRNase-based chemotherapeutic agents. Cytotoxic ptRNases should be characterized thoroughly in vitro before being tested in vivo. Below, we describe the state of the art in quantifying important parameters of ptRNase-mediated cytotoxicity, including cellular internalization, evasion of RI, inhibition of tumor cell proliferation in vitro, and inhibition of tumor growth in vivo. Several of these assays involve the use of fluorophores that can be tethered to ptRNases in a site-specific, nonperturbative manner.
Utility of small-molecule fluorophores
The constitutive fluorescence of traditional fluorophores (e.g., fluorescein) can lead to high background that obscures valuable information. To overcome this limitation, we designed fluorogenic label 1 (Fig. 11.4) , which consists of a rhodamine 110 core enshrouded by an esterase-inducible "trimethyl lock" and a maleimido group for conjugation. Fluorescence is unmasked only in the presence of intracellular esterases. Hence, the endocytic uptake of ptRNase-1 conjugates can be monitored by either fluorescence microscopy or flow cytometry (Lavis et al., 2006) .
We designed a second fluorescent label that is likewise amenable to thiol-reactive, site-specific conjugation. We had observed that the fluorescence of fluorescein-labeled RNase A decreases upon binding to RI because the protonated, nonfluorescent form of fluorescein is stabilized by the anionic RI (Abel et al., 2002) . The discrepancy between the phenolic pK a ¼ 6.30 of fluorescein and physiological pH diminishes the sensitivity of this assay. To address this problem, we synthesized 2 0 ,7 0 -diethylfluorescein, which has two electron-donating ethyl groups and a phenolic pK a of 6.61. Fluorescent probe 2 (2 0 ,7 0 -diethylfluorescein-5-iodoacetamide; Fig. 11 .4), which contains an iodoacetamido group for conjugation, enables a highly sensitive assay for the interaction of RI and ptRNases (Lavis et al., 2007) .
3.1.1. Site-specific conjugation of ptRNases to fluorophores Fluorescently labeled ptRNases have proven to be remarkably adaptable tools for a variety of assays. Nonetheless, as mammalian ptRNases contain multiple amino groups-including an essential one for catalysis in an active-site lysine residue (Messmore et al., 1995) -using amine-reactive reagents to crosslink or conjugate ptRNases can result in heterogeneity and inactivation. To overcome this problem, we install cysteine residues at inconsequential positions in ptRNases, allowing for site-specific conjugation to fluorophores. Both RNase A and RNase 1 contain eight cysteine residues that form four disulfide bonds in the native enzyme. To enable attachment of a thiol-reactive fluorophore, we introduce a cysteine residue at position 19 using site-directed mutagenesis. Position 19 is an optimal location because attachment of fluorophore groups there does not interfere with catalytic activity, RI binding, or cell-surface interactions (Fig. 11.3) . Further, this residue is in a solvated loop that is inconsequential for protein stability (Abel et al., 2002) . Free-cysteine variants are produced and purified by methods described previously for other ptRNase variants (Leland et al., 1998) , with the following modifications.
To ensure that the free cysteine residue does not suffer irreversible oxidation to a sulfinic or sulfonic acid, O 2 (g) must be removed from the buffers used in the purification process. Following initial purification, the free thiol group at position 19 is protected as a mixed disulfide by reaction with a fourfold molar excess of 5,5 0 -dithiobis(2-nitrobenzoic acid) (DTNB). Immediately following purification by gel-filtration chromatography, pooled protein fractions are adjusted to become 8% (w/v) in 1.0 M Tris-HCl buffer, pH 8.0, containing EDTA (10 mM). DTNB is dissolved in a small quantity of ethanol and then brought to 5 mM with 20 mM HEPES-NaOH buffer, pH 8.0. Upon addition of DTNB to the protein solution, a yellow color is observed due to the production of 2-nitro-5-thiobenzoic acid (NTB). The resulting mixture is dialyzed against several liters of 20 mM sodium acetate buffer, pH 5.0, overnight at 4 C to remove unreacted NTB. NTB-protected ribonucleases are then purified further with cation-exchange chromatography and stored at 4 C until needed for conjugation. Immediately prior to fluorophore attachment, NTB-protected ptRNases are deprotected with a fourfold molar excess of dithiothreitol and desalted by chromatography. Deprotected ptRNases are incubated for 6 h at 25 C with a 10-fold molar excess of fluorophore in phosphate-buffered saline (PBS) . N,N-Dimethylformamide ( 10%, v/v) can be added to the reaction mixture to increase fluorophore solubility. Following the conjugation reaction, the solution is dialyzed against 20 mM sodium acetate buffer, pH 5.0, and then purified again with reverse-phase HPLC to separate labeled and unlabeled protein. The molecular mass of each conjugate is verified by mass spectrometry prior to its use in assays.
3.1.2. Assessing cellular internalization with fluorescence spectroscopy The internalization of a ptRNase-1 conjugate into live cells can be visualized with fluorescence microscopy. The rate of ptRNase internalization can be quantified with flow cytometry. These analyses can be used with both adherent and nonadherent cell lines.
To quantify internalization, mammalian cells from nearly confluent flasks are collected by centrifugation and resuspended at a density of 10 6 cells/ml in fresh medium that is appropriate to the cell type. A ptRNase-1 conjugate is added (to 10 mM) to 250 ml of medium containing 10 6 cells/ml of cells. An unlabeled ptRNase can serve as a negative control. The cells are incubated at 37 C for known times, typically 2 h. During this timeframe, we have observed that only a small fraction of labeled ptRNases are taken up by cells; therefore, we assume that the rate of internalization is not limited by substrate concentration. Further, we do not observe any significant exocytosis of labeled ptRNases by confocal microscopy (Lavis et al., 2006) . To quench internalization, cells are collected by centrifugation at 1000 rpm for 5 min at 4 C, washed once with ice-cold PBS, and resuspended in 250 ml of PBS. Samples are kept on ice until their analysis. The fluorescence of unmasked 1 can be detected by flow cytometry using a 530/30-nm band-pass filter. Total cell viability can be determined by staining with propidium iodide, which can be detected through a 660-nm long-pass filter. The mean channel fluorescence intensity of 20,000 viable cells are determined for each sample and used for subsequent analyses. To determine the steady-state rate constant (k I ) for ptRNase internalization, fluorescence intensity data is fitted to Eq. (11.1), where F max is the fluorescence intensity upon reaching the steady state and k I is the first-order rate constant for ptRNase internalization into cells.
3.1.3. Evaluating RI evasion with fluorescence spectroscopy Traditionally, the stability of a RIÁRNase complex has been determined by measuring the inhibition of catalytic activity. The K i values obtained by this method are lower than the concentration of wild-type RNase 1 used in the experiment itself. Accordingly, these values can only be an upper limit for the true K d value. To more accurately measure the binding of ptRNases to RI, the dissociation rate of an RIÁptRNase complex is determined by monitoring the release of a ptRNase-2 conjugate over time (Fig. 11.5 ). To calculate the value of K d of a RIÁptRNase complex, the value of k a is assumed to be similar to that for the association of hRI with angiogenin or RNase A. These k a values are within twofold of each other and are close to the diffusion limit (Lee et al., 1989) . Thus, the k a value of homologous ptRNases is assumed to be equivalent to RNase A. The dissociation rate of the complex between RI and a ptRNase-2 conjugate can be determined by following the increase in fluorescence upon complex dissociation (Fig. 11.5) . A ptRNase-2 conjugate (100 nM) in PBS containing tris(2-carboxyethyl)phosphine (100 mM) and bovine serum albumin (0.10 mg/ml; Sigma Chemical) is added to a 96-well microtiter plate, and the initial fluorescence is measured with a plate reader. RI is then added at equimolar concentrations and incubated with labeled ptRNase at 25 C for 5 min. A 50-fold molar excess of human angiogenin or RNase 1 (5 mM) is added to scavenge dissociated complex, and the change in fluorescence is measured at various time points. To insure that the proteins maintain their folded conformation for the duration of the experiment, additional data points should be monitored under the same conditions, only without the addition of the 50-fold molar excess of angiogenin. To account for indeterminate error, data are the mean (AE SE) from six solutions normalized for the fluorescence of four solutions of labeled ptRNase (100 nM) in the absence of RI. Fluorescence data are fitted to Eq. (11.2) to determine the dissociation rate constant (k d ), wherein F 0 is the fluorescence before the addition of angiogenin, and F 1 is the fluorescence before RI addition. The equilibrium dissociation constant (K d ) for the RIÁptRNase complex can be determined with Eq. (11.3) and the known value for the association rate constant of RNase A (k a ¼ 3.4 Â 10 8 M -1 s -1
; Lee et al., 1989) .
Measuring inhibition of tumor-cell proliferation in vitro
Multiple assays exist for measuring the effects of ribonucleases on cultured cells in vitro. We choose to use the following cell proliferation assay because of its very high reproducibility. Cytotoxicity is evaluated by measuring the incorporation of [methyl-3 H]thymidine into newly synthesized DNA of either adherent or nonadherent cells. Although this assay measures the synthesis of DNA that is necessary for cell proliferation, the data also report on cell death. As revealed by trypan blue dye exclusion, the number of nonviable cells increases upon treatment with a toxic ptRNase .
RI·ptRNase-2
ptRNase-2 Figure 11 .5 Assay for evaluating K d , which is the equilibrium dissociation constant of an RIÁptRNase complex (Lavis et al., 2007) . Dissociation of the complex leads to an increase in fluorescence. The assay can also be used to evaluate the affinity of an unlabeled competitor ptRNase with a K d value that is higher than the labeled ptRNase.
A significant portion of these treated cells also display enhanced labeling with the apopotic marker Annexin V (T.Y. Chao and R.T. Raines, unpublished results) . Microscopic analyses of treated cells indicate an apoptotic morphology, including the formation of apoptotic bodies, nuclear condensation, and fragmentation. The extent of cell viability and apoptotic morphology correlates well with [methyl-3 H]thymidine incorporation . Thus, ptRNases render apoptosis upon target cells, and our assay of the inhibition of DNA synthesis reports on cytotoxicity.
Cells, such as human erythroleukemia line K-562 (ATCC; Manassas, VA), are grown in Roswell Park Memorial Institute (RPMI) 1640 medium (Mediatech, Herndon, VA) supplemented with fetal bovine serum (FBS; 10%, v/v), penicillin (100 units/ml), and streptomycin (100 mg/ml), and maintained at 37 C in a humidified atmosphere containing CO 2 (g) (5%, v/v). Aliquots (95 ml) of cultured cells (10 5 cells/ml) are placed in a microtiter plate, and sterile solutions (5 ml) of a ptRNase in PBS are added to the aliquots. Cells are incubated in the presence or absence of ribonucleases for 44 h, followed by a 4 h pulse with [methyl- 3 H]thymidine (0.2 mCi per well). Cells are then harvested onto glass fiber filters by using, for example, a PHD cell harvester (Cambridge Technology, Watertown, MA) and lysed by the passage of several milliliters of water through the filters. The filter retains DNA and other cellular macromolecules, while small molecules, including unincorporated radiolabel, pass through. After washing extensively with water, the filters are dried with methanol and counted by using a liquid scintillation counter. Results from the cytotoxicity assay are reported as the percentage of [methyl- 3 H]thymidine incorporation into the DNA of PBS-treated control cells. All assays should be repeated at least three times to lessen indeterminate error. Values of IC 50 , which is the concentration of ribonucleases that decreases cell proliferation by 50%, are calculated by fitting the data using nonlinear regression analysis to a sigmoidal dose-response curve (Eq. (11.4)), in which y is the DNA synthesis following the [methyl- 3 H]thymidine pulse and h is the slope of the curve.
Measuring inhibition of tumor-cell proliferation in vivo
The most compelling method to measure the therapeutic effects of a cytotoxic ptRNase comes from in vivo analysis of tumor growth inhibition. This assay utilizes human tumor xenografts grown in the flanks of nude mice. Here, we describe our method for analyzing the effect on the growth of these tumors. We use the human tumor cell lines DU145 (prostate cancer) and A549 (non-small cell lung cancer) for their ability to proliferate in mice, their low rate of spontaneous regression, and their known sensitivity to RI-evasive variants of RNase A (Rutkoski et al., 2005) . Moreover, each line represents a clinically relevant target that is used often in the testing of new chemotherapeutic agents. DU145 cells are grown in Dulbecco's modified Eagle's medium (ATCC) containing FBS (10%, v/v); A549 cells are grown in F12K medium (ATCC) containing FBS (10%, v/v). Cells ($10 6 ) are implanted into a rear flank of 5-6-week-old male homozygous (nu/nu) nude mice. Tumors are allowed to grow to a volume of !75 mm 3 before the initiation of treatment. All test compounds are diluted in sterile PBS. All treatments are administered either by intraperitoneal (i.p.) injection or orally with a gavage needle (p.o.) for comparator chemotherapeutics, with the volume of administered solution based upon the body weight of the animal (10 ml/g). It is important to establish a dose and administration schedule that is effective with a specific cytotoxic ptRNase and tumor cell type. We have found that for mice bearing DU145 prostate carcinoma tumors, a dose of 15 mg/kg (i.p., qd Â 5) of several monomeric ptRNase variants is optimal for eliciting maximum inhibition of tumor growth while minimizing off-target effects, as monitored by change in body weight. Similarly, we have found that frequent administration (qd Â 5) achieves maximal tumor growth inhibition as compared to a single large dose (1 Â wk). On the other hand, trimeric conjugates of cytotoxic RNase A variants can be administered less frequently and at a lower dose with comparable effect (Rutkoski et al., 2010) . We speculate that the increased hydrodynamic radii of these trimeric conjugates result in enhanced persistence in circulation, as is observed with ptRNase-PEG conjugates (Rutkoski et al., 2011) . Animal body weight should be monitored continually throughout the experiment as an indicator of drug tolerance.
Treatment with all agents should be ongoing throughout the entire experiment, with a control set of animals treated with vehicle alone. Comparators can include approved chemotherapeutic agents, such as docetaxel (15 mg/kg; i.p., 1 Â wk), cisplatin (6 mg/kg; i.p., 1 Â wk), and erlotinib (100 mg/kg; p.o., 2 Â wk). Tumor size should be measured twice-weekly using calipers, and tumor volume (mm 3 ) can be estimated by using the formula for a spheroid (Eq. (11.5) 
Prospectus
We have engineered mammalian ptRNases into useful cytotoxins. Through the use of novel, sensitive assays, we have been able to reveal the contribution of various parameters toward cytotoxicity. Still, mechanistic issues remain unclear, involving ptRNase translocation from endosomes to the cytosol and the specific RNA targets of ptRNases. Novel assays to illuminate these issues-and exploit them therapeutically-are being developed in our laboratory. Further work is directed at enhancing the circulating half-life of ptRNases in vivo using pegylation or glycosylation.
ptRNases have shown exceptional applicability as model proteins for multifaceted drug design. The potential therapeutic value of ptRNases has been extended beyond cancer with the creation of zymogens that can be engineered to be disease specific. To date, protease-activatable ptRNase zymogens have been developed to combat malaria, hepatitis C, and HIV ( Johnson et al., 2006; Plainkum et al., 2003; Turcotte and Raines, 2008) . Another member of the ptRNase family, angiogenin, has been designed as a hyperactive variant capable of enhanced neovascularization (Dickson et al., 2009) . Continued efforts to engineer this remarkable family of proteins will no doubt add even more therapeutic value.
